Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Malaysia.
Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Int J Mol Sci. 2021 Jul 10;22(14):7425. doi: 10.3390/ijms22147425.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents significant social, economic and political challenges worldwide. SARS-CoV-2 has caused over 3.5 million deaths since late 2019. Mutations in the spike (S) glycoprotein are of particular concern because it harbours the domain which recognises the angiotensin-converting enzyme 2 (ACE2) receptor and is the target for neutralising antibodies. Mutations in the S protein may induce alterations in the surface spike structures, changing the conformational B-cell epitopes and leading to a potential reduction in vaccine efficacy. Here, we summarise how the more important variants of SARS-CoV-2, which include cluster 5, lineages B.1.1.7 (Alpha variant), B.1.351 (Beta), P.1 (B.1.1.28/Gamma), B.1.427/B.1.429 (Epsilon), B.1.526 (Iota) and B.1.617.2 (Delta) confer mutations in their respective spike proteins which enhance viral fitness by improving binding affinity to the ACE2 receptor and lead to an increase in infectivity and transmission. We further discuss how these spike protein mutations provide resistance against immune responses, either acquired naturally or induced by vaccination. This information will be valuable in guiding the development of vaccines and other therapeutics for protection against the ongoing coronavirus disease 2019 (COVID-19) pandemic.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的出现给全球带来了重大的社会、经济和政治挑战。自 2019 年底以来,SARS-CoV-2 已导致超过 350 万人死亡。刺突(S)糖蛋白的突变尤其令人关注,因为它包含识别血管紧张素转换酶 2(ACE2)受体的结构域,也是中和抗体的靶标。S 蛋白的突变可能会引起表面刺突结构的改变,改变构象 B 细胞表位,并导致疫苗效力的潜在降低。在这里,我们总结了 SARS-CoV-2 的一些更重要的变异株,包括第 5 簇、谱系 B.1.1.7(Alpha 变异株)、B.1.351(Beta)、P.1(B.1.1.28/Gamma)、B.1.427/B.1.429(Epsilon)、B.1.526(Iota)和 B.1.617.2(Delta),它们在各自的刺突蛋白中发生突变,通过提高与 ACE2 受体的结合亲和力,增强病毒适应性,并导致感染性和传染性的增加。我们进一步讨论了这些刺突蛋白突变如何提供对免疫反应的抵抗力,无论是自然获得的还是疫苗诱导的。这些信息对于指导针对持续的 2019 年冠状病毒病(COVID-19)大流行的疫苗和其他治疗方法的开发将是有价值的。